8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          An effective HIV vaccine will likely need to induce broad and potent CTL responses. Epitope-based vaccines offer significant potential for inducing multi-specific CTL, but often require conjugation to T helper epitopes or carrier moieties to induce significant responses. We tested hybrid DNA vaccines encoding one or more HIV or SIV CTL epitopes fused to a hepatitis B core antigen (HBcAg) carrier gene as a means to improve the immunogenicity of epitope-based DNA vaccines. Immunization of mice with a HBcAg-HIV epitope DNA vaccine induced CD8+ T cell responses that significantly exceeded levels induced with DNA encoding either the whole HIV antigen or the epitope alone. In rhesus macaques, a multi-epitope hybrid HBcAg-SIV DNA vaccine induced CTL responses in rhesus macaques to 13 different epitopes, including 3 epitopes that were previously not detected in SIV-infected macaques. These data demonstrate that immunization with hybrid HBcAg-epitope DNA vaccines is an effective strategy to increase the magnitude and breadth of HIV-specific CTL responses.

          Related collections

          Author and article information

          Journal
          0110674
          8015
          Virology
          Virology
          Virology
          0042-6822
          1096-0341
          30 April 2009
          11 April 2007
          01 August 2007
          08 December 2018
          : 364
          : 2
          : 245-255
          Affiliations
          [1 ] PowderJect Vaccines, Inc., Madison, WI, 53562
          [2 ] Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53715
          [3 ] Wisconsin Regional Primate Research Center, Madison, WI, 53715
          Author notes
          [* ]Corresponding Author: Deborah H. Fuller, Department of Molecular Genetics and Biochemistry, University of Pittsburgh, School of Medicine, RIDC Park, 260 Kappa Drive, Pittsburgh, PA 15238, Ph: 412-967-6505; Fax: 412-967-6568, Email: dfuller@ 123456pitt.edu
          [4]

          Department of Molecular Genetics and Biochemistry, University of Pittsburgh, School of Medicine, Pittsburgh, PA, 15238

          [5]

          Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129

          [6]

          Recombiworks, Cranberry, PA, 16066

          [7]

          Fred Hutchinson Cancer Research Center, Seattle, WA 98109

          [8]

          ALZA Corporation, Drug-Device Research, Mountain View, CA 94039-7210

          Article
          PMC6286304 PMC6286304 6286304 nihpa25780
          10.1016/j.virol.2007.02.024
          6286304
          17428516
          8d5f21dd-a32c-4aa9-8ada-461e31582b01
          History
          Categories
          Article

          Comments

          Comment on this article

          scite_

          Similar content203

          Cited by9